Statement 16 May 2024

Statement at UN multistakeholder hearing on antimicrobial resistance

On 15 May 2024, IFPMA delivered a statement at the UN multistakeholder hearing on antimicrobial resistance, held in New York. The hearing represented an opportunity for all stakeholders to contribute to the ongoing preparatory process for the high-level meeting on AMR, held in September 2024.

Read more
Statement 15 May 2024

IFPMA statement on research with vulnerable populations within the scope of the World Medical Association (WMA) Declaration of Helsinki revision

On 14-15 May 2024, IFPMA was represented at a targeted interdisciplinary discussion within the scope of the WMA Declaration of Helsinki revision. The aim of the meeting was to foster discussion with experts on the paragraphs in the Declaration of Helsinki focused on vulnerable people in research, with a view to contribute the findings to...

Read more
Report 14 May 2024

From resistance to resilience: what could the future antibiotic pipeline look like?

In a new report, IFPMA reviews the antibiotic pipeline data against bacterial pathogens identified by the WHO and other public health agencies as of the greatest concern, and presents modelling data on the future of the pipeline. 

Read more
Statement 13 May 2024

WIPO Diplomatic Conference on Genetic Resources and Associated Traditional Knowledge

On 13 May 2024, IFPMA delivered a statement at the WIPO Diplomatic Conference on Genetic Resources and Associated Traditional Knowledge in Geneva, Switzerland. IFPMA and our members support predictable access to genetic resources that can be the starting point for biopharmaceutical research and development. We are concerned that the outcome of this Diplomatic Conference could...

Read more
Expert insight 25 Apr 2024

Adult immunisation programmes boost public health and economic prosperity

Vaccinating adults helps ease pressures on healthcare providers and delivers benefits to society more broadly. It’s time to realise that potential value in full. Vaccines are commonly associated with childhood, but their importance extends into adulthood and old age. Recent studies highlighted that adult vaccination programmes are not only beneficial for individual health but also...

Read more
Expert insight 25 Apr 2024

How IP enables accelerated progress on the Sustainable Development Goals

The Sustainable Development Goals (SDGs) emerged from a collective ambition to create a blueprint for global action, charting the path to a better future for everyone. But, with just over five years to 2030, progress is lagging. Collective, concerted effort, supported by technological solutions, is required to achieve these goals. To unlock such innovations, the...

Read more
Position paper 24 Apr 2024

Our position on the Global Plastics “Instrument”

Ahead of negotiations on a Global Plastics “Instrument”, the innovative pharmaceutical industry put together its position. Key takeaways include: IFPMA supports an overall ambitious UN Global Plastics “Instrument” that creates globally harmonized plastic regulations. This is key to securing the scale and effect needed if we are to succeed in transitioning away from plastic where...

Read more
Statement 23 Apr 2024

Fourth meeting of the Intergovernmental Negotiating Committee (INC-4) on plastics pollution

On 23 April 2024, IFPMA submitted a statement to the Fourth Meeting of the Intergovernmental Negotiating Committee (INC-4) on plastics pollution in Ottawa, Canada. The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) lends its full support to an ambitious UN Global Plastics “Instrument” that can help create globally harmonized rules on plastic. This is...

Read more
Statement 22 Apr 2024

Eighth Meeting of the Working Group on Amendments to the International Health Regulations (2005)

On 22 April 2024, IFPMA delivered a statement at the Eighth Meeting of the Working Group on Amendments to the International Health Regulations (2005) in Geneva, Switzerland.

Read more
Position paper 18 Apr 2024

How we are contributing to global pharmaceutical standards

The evolving global pharmaceutical regulatory environment and the increasing interest of new countries in joining the ICH highlights the importance of maintaining consistent interpretation and implementation of ICH guidelines among industry and regulatory authorities worldwide. The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), along with other ICH Members and Observers, has an important role...

Read more
Expert insight 18 Apr 2024

Advancing regulatory reliance on a global scale

Next week, Japan will host expert discussions on strengthening regulatory systems, fostering international collaboration, and advancing towards universal health coverage. This discussion is part of the Asia Partnership Conference of Pharmaceutical Associations (APAC), an industry-driven initiative focused on expediting the availability of innovative medicines across Asia. For more than 10 years, APAC has served as...

Read more
External study 17 Apr 2024

The socio-economic value of adult immunisation programmes

Download this OHE report, commissioned by IFPMA, to learn more about the socio-economic value of adult vaccination programems on individual lives and societies at large.

Read more